Pecci A - Search Results

1

International prognostic scoring system and other prognostic systems for myelodysplastic syndromes.

Balduini CL, Guarnone R, Pecci A, Centenara E, Ascari E. Balduini CL, et al. Among authors: pecci a. Blood. 1997 Nov 15;90(10):4232-4. Blood. 1997. PMID: 9354697 Free article. No abstract available.

2

Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.

Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E. Invernizzi R, et al. Among authors: pecci a. Haematologica. 1997 Sep-Oct;82(5 Suppl):9-12. Haematologica. 1997. PMID: 9402747 Clinical Trial.

3

Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.

Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E. Invernizzi R, et al. Among authors: pecci a. Haematologica. 1997 Nov-Dec;82(6):660-3. Haematologica. 1997. PMID: 9499664 Clinical Trial.

4

Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes.

Balduini CL, Guarnone R, Pecci A, Centenara E, Ascari E. Balduini CL, et al. Among authors: pecci a. Leukemia. 1998 Oct;12(10):1655-6. doi: 10.1038/sj.leu.2401165. Leukemia. 1998. PMID: 9766515 No abstract available.

5

The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution.

Balduini CL, Guarnone R, Pecci A, Centenara E, Invernizzi R, Ascari E. Balduini CL, et al. Among authors: pecci a. Haematologica. 1999 Jan;84(1):12-6. Haematologica. 1999. PMID: 10091387

6

Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes.

Invernizzi R, Pecci A, Bellotti L, Ascari E. Invernizzi R, et al. Among authors: pecci a. Leuk Lymphoma. 2001 Jul;42(3):481-9. doi: 10.3109/10428190109064605. Leuk Lymphoma. 2001. PMID: 11699413

7

Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes.

Invernizzi R, Pecci A, Travaglino E, Gobbi PG, Malabarba L, Ramajoli I, Ascari E. Invernizzi R, et al. Among authors: pecci a. Br J Haematol. 2002 Jul;118(1):246-50. doi: 10.1046/j.1365-2141.2002.03569.x. Br J Haematol. 2002. PMID: 12100155 Free article.

8

Altered cytoskeleton organization in platelets from patients with MYH9-related disease.

Canobbio I, Noris P, Pecci A, Balduini A, Balduini CL, Torti M. Canobbio I, et al. Among authors: pecci a. J Thromb Haemost. 2005 May;3(5):1026-35. doi: 10.1111/j.1538-7836.2005.01244.x. J Thromb Haemost. 2005. PMID: 15869600 Free article.

9

Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).

Pecci A, Granata A, Fiore CE, Balduini CL. Pecci A, et al. Nephrol Dial Transplant. 2008 Aug;23(8):2690-2. doi: 10.1093/ndt/gfn277. Epub 2008 May 23. Nephrol Dial Transplant. 2008. PMID: 18503011 No abstract available.

10

Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.

Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T, Bozzi V, Mezzasoma AM, Melazzini F, Balduini CL. Pecci A, et al. Blood. 2010 Dec 23;116(26):5832-7. doi: 10.1182/blood-2010-08-304725. Epub 2010 Sep 15. Blood. 2010. PMID: 20844233 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters